Racura Oncology Presents Key MYC Silencing Data at Major Cancer Conference

ShareCafe: Racura Oncology Ltd (ASX: RAC) has announced the presentation of significant mechanism of action data concerning its lead asset, (E,E)-bisantrene, at the prestigious 2026 American Association of Cancer Research (AACR) Annual Meeting. Read the article here.

Latest Posts

L36, 1 Macquarie Place Sydney NSW 2000
E: info@racuraoncology.com T: +61 2 8051 3043
© 2026 Racura Oncology | Privacy Policy
Sign up to receive the most recent news and updates
Sign up to receive the most recent news and updates
Racura Oncology
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.